Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Virol. Sep 25, 2025; 14(3): 107903
Published online Sep 25, 2025. doi: 10.5501/wjv.v14.i3.107903
Published online Sep 25, 2025. doi: 10.5501/wjv.v14.i3.107903
Real-life practice of Kelleni’s protocol in treatment and post exposure prophylaxis of SARS-CoV-2 HV.1 and JN.1 subvariants
Mina Thabet Kelleni, Department of Pharmacology, College of Medicine, Minia University, Minya 61519, Egypt
Author contributions: Kelleni MT is responsible for all aspects of the writing and publication process of the manuscripts.
Conflict-of-interest statement: Dr. Kelleni has nothing to disclose.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Mina Thabet Kelleni, MD, PhD, Assistant Professor, Department of Pharmacology, College of Medicine, Minia University, Main Road Shalaby Land, Minya 61519, Egypt. mina.kelleni@mu.edu.eg
Received: April 2, 2025
Revised: May 17, 2025
Accepted: July 24, 2025
Published online: September 25, 2025
Processing time: 178 Days and 19.1 Hours
Revised: May 17, 2025
Accepted: July 24, 2025
Published online: September 25, 2025
Processing time: 178 Days and 19.1 Hours
Core Tip
Core Tip: Coronavirus disease 2019 (COVID-19) has claimed the lives of over seven million people worldwide. Most deaths have occurred among high-risk patients, making it crucial to find a protocol that is effective for post-exposure prophylaxis in this pandemic and future ones. This article provides insight into how Kelleni’s protocol was successfully and safely used to save lives among high-risk groups of COVID-19 patients amidst the ongoing evolution of severe acute respiratory syndrome coronavirus 2.